Mon, 30th July 2001

New Zealand Meningococcal Vaccine Sought

 
The Ministry of Health has contracted Californian biotech company Chiron Corporation to develop a vaccine to combat menningococcal disease, which has social costs to New Zealand of an estimated $75 million a year.

A specific vaccine is needed because the strain of meningococcal group B bacterium responsible for the NZ epidemic has subtle differences from other strains.

Director-General of Health Dr Karen Poutasi welcomed the contract as a highly significant first step in reducing the toll the disease takes on New Zealanders, but cautioned there was still a lot more work to be done.

"Anyone who has had a family member contract meningococcal disease knows what an aggressive and frightening illness it can be. It's frightening enough even to think your sick child's symptoms could be those of meningococcal disease," Dr Poutasi said.

"Symptoms in a very young child can include a fever and vomiting, or the child may refuse drinks or feeds, be excessively sleepy, or cry and be unsettled. A rash like blood spots under the skin may also appear at a later stage. It is important that the child see a doctor, as early treatment helps save lives."

So far this year there have been nearly 300 cases of meningococcal disease, resulting in 15 deaths.

CLEAR Net users
discuss the news here.

© Copyright 1999 NewsNet Ltd